Summary

Global Plasma Protease C1-Inhibitor Market is valued approximately USD 3752.3 million in 2023 and is anticipated to grow with a healthy growth rate of more than 17.72% over the forecast period 2024-2032. Plasma Protease C1-Inhibitor, also referred to as C1-INH or C1 esterase inhibitor, is a vital protein present in the blood. It plays a key role in regulating the complement system and controlling inflammation. As a natural inhibitor of several proteases, including C1s and C1r, which are components of the classical pathway of the complement system, C1-INH helps prevent excessive activation of the complement cascade. By doing so, it inhibits the production of inflammatory mediators, maintaining immune homeostasis and preventing tissue damage. The rising shift towards early diagnosis and improved awareness is a key trend that the supporting the growth of Global Plasma Protease C1-Inhibitor Market during the estimated period of 2024-2032. Growing awareness among the public and healthcare professionals about Hereditary Angioedema (HAE) is resulting in earlier diagnoses. This has led to a larger number of patients seeking treatment, consequently driving the market demand for C1-inhibitor therapies.

The rising prevalence of HAE globally is a significant driver for the demand for Plasma Protease C1-Inhibitor products, as they are crucial for managing and treating this rare genetic disorder. Accordingly, increased public and medical professional awareness of HAE leads to earlier diagnosis and a rise in patients seeking treatment. Besides HAE, Plasma Protease C1-Inhibitor products are being explored for their potential in treating other conditions related to complement system disorders and inflammatory diseases, contributing to market expansion. Moreover, rising investment in research and development, the discovery of new inhibitor drugs, growing product approvals and the development of promising pipeline drugs and novel therapies for treating hereditary angioedema are among the key factors propelling the global market growth during the estimated period. However, high price of esoteric testing procedures and stringent regulatory requirements is expected stifle market growth between 2022 and 2032.

The key regions considered for the global Plasma Protease C1-Inhibitor Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America leads the global Plasma Protease C1-Inhibitor market in terms of revenue due to the growing prevalence of Hereditary Angioedema (HAE). Also, pharmaceutical companies in North America are actively involved in researching and developing new and improved C1-inhibitor therapies. This includes exploring alternative delivery methods, extended-release formulations and even gene therapies for HAE. The region benefits from a robust healthcare infrastructure, frequent product approvals, and major market players offering effective treatments for HAE patients. Favorable regulatory policies and approvals for Plasma Protease C1-Inhibitor products are facilitating their accessibility and adoption in North America, contributing to market expansion. The market in Asia Pacific, on the other hand, is expected to grow at the fastest rate over the forecast period.

Major market player included in this report are:
CSL Limited (CSL Behring LLC)
Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
Ionis Pharmaceuticals, Inc.
Pharming Technologies B.V.
Centogene AG
BioCryst Pharmaceuticals
KalVista Pharmaceuticals, Inc.
Fresenius Kabi
Octapharma AG
Kedrion S.p.A.

The detailed segments and sub-segment of the market are explained below:

By Drug Type
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

By Dosage Form
Lyphophlised
Injectables


By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Global Plasma Protease C1-Inhibitor Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Global Plasma Protease C1-Inhibitor Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Drug Type
2.3.2. By Dosage Form
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Global Plasma Protease C1-Inhibitor Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Global Plasma Protease C1-Inhibitor Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Plasma Protease C1-Inhibitor Market Size & Forecasts by Drug Type 2022-2032
5.1. C1-inhibitors
5.2. Kallikrein Inhibitor
5.3. Selective Bradykinin B2 Receptor Antagonist
Chapter 6. Global Plasma Protease C1-Inhibitor Market Size & Forecasts by Dosage Form 2022-2032
6.1. Lyphophlised
6.2. Injectables
Chapter 7. Global Plasma Protease C1-Inhibitor Market Size & Forecasts by Region 2022-2032
7.1. North America Plasma Protease C1-Inhibitor Market
7.1.1. U.S. Plasma Protease C1-Inhibitor Market
7.1.1.1. Drug Type breakdown size & forecasts, 2022-2032
7.1.1.2. Dosage Form breakdown size & forecasts, 2022-2032
7.1.2. Canada Plasma Protease C1-Inhibitor Market
7.2. Europe Plasma Protease C1-Inhibitor Market
7.2.1. U.K. Plasma Protease C1-Inhibitor Market
7.2.2. Germany Plasma Protease C1-Inhibitor Market
7.2.3. France Plasma Protease C1-Inhibitor Market
7.2.4. Spain Plasma Protease C1-Inhibitor Market
7.2.5. Italy Plasma Protease C1-Inhibitor Market
7.2.6. Rest of Europe Plasma Protease C1-Inhibitor Market
7.3. Asia-Pacific Plasma Protease C1-Inhibitor Market
7.3.1. China Plasma Protease C1-Inhibitor Market
7.3.2. India Plasma Protease C1-Inhibitor Market
7.3.3. Japan Plasma Protease C1-Inhibitor Market
7.3.4. Australia Plasma Protease C1-Inhibitor Market
7.3.5. South Korea Plasma Protease C1-Inhibitor Market
7.3.6. Rest of Asia Pacific Plasma Protease C1-Inhibitor Market
7.4. Latin America Plasma Protease C1-Inhibitor Market
7.4.1. Brazil Plasma Protease C1-Inhibitor Market
7.4.2. Mexico Plasma Protease C1-Inhibitor Market
7.4.3. Rest of Latin America Plasma Protease C1-Inhibitor Market
7.5. Middle East & Africa Plasma Protease C1-Inhibitor Market
7.5.1. Saudi Arabia Plasma Protease C1-Inhibitor Market
7.5.2. South Africa Plasma Protease C1-Inhibitor Market
7.5.3. Rest of Middle East & Africa Plasma Protease C1-Inhibitor Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. CSL Limited (CSL Behring LLC)
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
8.3.3. Ionis Pharmaceuticals, Inc.
8.3.4. Pharming Technologies B.V.
8.3.5. Centogene AG
8.3.6. BioCryst Pharmaceuticals
8.3.7. KalVista Pharmaceuticals, Inc.
8.3.8. Fresenius Kabi
8.3.9. Octapharma AG
8.3.10. Kedrion S.p.A.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes